Quality by Design (QbD) driven Systematic Development of Nano-lipoidal Carrier of Poorly Water Soluble Anti-tubercular agent-Rifabutin.

References

• Esmail H, Barry CE, Young DB, et al. The ongoing challenge of latent tuberculosis. Philos Trans R Soc B Biol Sci. 2014;369(1645):20130437.
   PubMed Web of Science ®Google Scholar
• Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999;115(4):1033–1040.
   PubMed Web of Science ®Google Scholar
• Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
   PubMed Web of Science ®Google Scholar
• Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis, Mand. Douglas, Bennett’s Princ Pract Infect Dis. 2015;2787–2818.e5. DOI:https://doi.org/10.1016/B978-1-4557-4801-3.00251-4
   Google Scholar
• Maitra A, Bates S, Kolvekar T, et al. Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis. 2015;32:50–55.
   PubMed Web of Science ®Google Scholar
• An Q, Li C, Chen Y, et al. Repurposed drug candidates for antituberculosis therapy. Eur J Med Chem. 2020;192:112175.
   PubMed Web of Science ®Google Scholar
• Patil K, Bagade S, Bonde S, et al. Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities, biomed. Pharmacother. 2018;99:735–745.
   Web of Science ®Google Scholar
• Rani J, Silla Y, Borah K, et al. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis. J Biomol Struct Dyn. 2020;38(9):2521–2532.
   PubMed Web of Science ®Google Scholar
• Rodrigues L, Cravo P, Viveiros M. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. Expert Rev Anti Infect Ther. 2020;1–17. DOI:https://doi.org/10.1080/14787210.2020.1760845
   Google Scholar
• Lan NT, Thu NT, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9(1):1–10.
   Web of Science ®Google Scholar
• Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993;329(12):828–833.
   PubMed Web of Science ®Google Scholar
• Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public health service task force on Prophylaxis and therapy for Mycobacterium avium complex. N Engl J Med. 1993;329(12):898–904.
   PubMed Web of Science ®Google Scholar
• Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1989;33(8):1237–1241.
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22(Suppl1):S15–21.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA), Quality by design for ANDAs : an example for immediate-release dosage forms, Fda. (2012) 1–107.
   Google Scholar
• Maguire J, Peng D, How to identify critical quality attributes and critical process parameters, FDA/PQRI 2nd Conf. (2015) 1–40.  North Bethesda, Maryland. http://pqri.org/wp-content/uploads/2015/10/01-How-to-identify-CQA-CPP-CMA-Final.pdf.
   Google Scholar
• Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis. 2005;85(5–6):415–420.
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target. 2011;19(3):219–227.
   PubMed Web of Science ®Google Scholar
• Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery, drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149–155.
   PubMed Web of Science ®Google Scholar
• Zhu RR, Qin LL, Wang M, et al. Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles. Nanotechnology. 2009;20(5):1–7.
   Web of Science ®Google Scholar
• Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target. 2009;17(10):777–787.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85(4):227–234.
   PubMed Web of Science ®Google Scholar
• Kakkar V, Singh S, Singla D, et al. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55(3):495–503.
   PubMed Web of Science ®Google Scholar
• Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133(3):238–244.
   PubMed Web of Science ®Google Scholar
• Shokry M, Hathout RM, Mansour S. Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: augmented in-vivo efficacy and safe histological profile. Int J Pharm. 2018;545(1–2):229–239.
   PubMed Web of Science ®Google Scholar
• Jadhav M, Khan T, Bhavsar C, et al. Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs, expert opin. Drug Deliv. 2019;16:687–699.
   Web of Science ®Google Scholar
• Mehta M, Sharma DN, Vyas M, et al. Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases. Chem Biol. 2019 May 1; 304:10-19.
   Google Scholar
• ICH, Q8 (R2), Pharmaceutical Development, 8 (2009).
   Google Scholar
• Raina H, Kaur S, Jindal AB. Development of efavirenz loaded solid lipid nanoparticles: risk assessment, quality-by-design (QbD) based optimisation and physicochemical characterisation. J Drug Deliv Sci Technol. 2017;39:180–191.
   Web of Science ®Google Scholar
• Park SY, Kang Z, Thapa P, et al. Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach. Int J Pharm. 2019;566:229–238.
   PubMed Web of Science ®Google Scholar
• Amasya G, Badilli U, Aksu B, et al. Quality by design case study 1: design of 5-fluorouracil loaded lipid nanoparticles by the W/O/W double emulsion — solvent evaporation method. Eur J Pharm Sci. 2016;84:92–102.
   PubMed Web of Science ®Google Scholar
• Sakshi Guleria SB. Formulation and optimization of Liposomal delivery vehicle of an anti-cancer drug exemestane by BOX-behnken design. J Pharm Res. 2014;8.
   Google Scholar
• Rane S, Prabhakar B. Optimization of paclitaxel containing pH-sensitive liposomes by 3 factor, 3 level box-behnken design. Indian J Pharm Sci. 2013;75(4):420–426.
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Dusunge SB, Gundare SA. Xyloglucanased microspheres for pulmonary delivery of rifabutin dry powder inhaler. Int J Pharm Sci Nanotechnol. 2017;10(3):3709–3714.
   Google Scholar
• FDA, Nonclinical Studies for the safety evaluation of pharmaceutical excipients. Center for drug evaluation and research (CDER).U.S.A, 2005. Accessed August 19, 2020. https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/nonclinical-studies-safety-evaluation-pharmaceutical-excipients
   Google Scholar